Search results for "Renal function"

showing 10 items of 381 documents

Evaluation of oxidative stress in hypertensive patients with transplanted kidney

2005

medicine.medical_specialtyKidneybusiness.industryRenal functionmedicine.diseasemedicine.disease_causeIsoprostanesNitric oxidechemistry.chemical_compoundmedicine.anatomical_structureReperfusion therapyBlood pressurechemistryInternal medicineInternal MedicinemedicineCardiologybusinessKidney transplantationOxidative stressAmerican Journal of Hypertension
researchProduct

99mTechnetium-Mercaptoacetyltriglycin (MAG3) zum Nachweis von Nierenveränderungen nach extrakorporaler Stoßwellenlithotripsie

1992

Extracorporeal shock wave lithotripsy (ESWL) has become the treatment of choice for urinary calculi. 117 patients were studied prospectively with 99mTc mercaptoacetyltriglycine (MAG3) before and after ESWL. 79 (66%) of the 119 kidneys treated had abnormal findings. Of these 63/119 (53%) had abnormal scans. 41 (65%) had focal lesions with a delayed intrarenal transport. The remaining 22 had a diffuse delay of intrarenal transport. A loss of relative renal function of 3% and more compared to the pretreatment values was observed in 50/119 (42%) patients. 99mTc MAG3 should be done routinely together with radiologic tests (CT or MRI) before and after ESWL to select the patients at risk for post …

medicine.medical_specialtyKidneybusiness.industrymedicine.medical_treatmentUrinary systemUrologychemistry.chemical_elementRenal functionLithotripsyTechnetiumExtracorporeal shock wave lithotripsyTechnetium Tc 99m Mertiatidemedicine.anatomical_structurechemistrymedicineRadiology Nuclear Medicine and imagingbusinessProspective cohort studyRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Die lokale Fibrinolyse bei Nierenarterienverschlüssen

1990

The indications and technique of local fibrinolysis therapy of acute renal artery occlusions are discussed in relation to four patients. Because of the short period for which ischaemia is tolerated by the kidney, the result of treatment depends largely on the time interval between occlusion and the beginning of treatment. Partial perfusion of the renal artery was obtained in three patients. Since the "ischaemia time" of the kidneys had been exceeded, it was not possible to obtain complete restitution of renal function in any of these patients.

medicine.medical_specialtyKidneymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentIschemiaRenal functionmedicine.diseaseSurgerymedicine.anatomical_structureInternal medicinemedicine.arteryAngiographyOcclusionFibrinolysismedicineCardiologyRadiology Nuclear Medicine and imagingRenal arterybusinessPerfusionRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting

2019

Real-life data confirming the favourable renal outcome in patients with heart failure (HF) treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We evaluated the renal effects of Sacubitril/Valsartan in a real-life sample of HF patients. Observational analysis of 54 consecutive outpatients affected by HF with reduced ejection fraction (HFrEF) and clinical indication for Sacubitril/Valsartan. Patients were evaluated at baseline (T0) and after six (T6) and twelve (T12) months after initiating Sacubitril/Valsartan and compared with a group of 30 historical controls. Mean age: 65.5 ± 11.7 years. Older patients: 29 (53.7%). Mean baseline estimated glomeru…

medicine.medical_specialtyMEDLINETetrazolesHeart failureLifeInternal MedicinemedicineHumansKidney dysfunctionSacubitril-ValsartanIntensive care medicinebusiness.industryAminobutyratesBiphenyl CompoundsFollow up studiesSacubitril/Valsartanmedicine.diseaseIm - OriginalDrug CombinationsValsartanHeart failureBlood pressureEmergency MedicineValsartanbusinessSacubitril ValsartanFollow-Up StudiesRenal functionmedicine.drug
researchProduct

Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease

2020

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A r…

medicine.medical_specialtyMedicina030232 urology & nephrologyRenal functionReviewsType 2 diabetes030204 cardiovascular system & hematologyDiabetic nephropathy03 medical and health sciences0302 clinical medicineSodium-Glucose Transporter 2Internal medicineDiabetes mellitusDiabetic nephropathiesmedicineChronic renal failureHumansDiabetic NephropathiesDiabetic kidney diseaseESRDSodium-Glucose Transporter 2 InhibitorsTransplantationbusiness.industryType 2 diabetesNefropaties diabètiquesmedicine.diseasePrognosisBlood pressureDiabetes Mellitus Type 2NephrologyHeart failureSodium/Glucose Cotransporter 2Insuficiència renal crònicabusinessSGLT2 inhibitorsKidney disease
researchProduct

GLP-1 Receptor agonists and diabetic kidney disease: A call of attention to nephrologists

2020

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 r…

medicine.medical_specialtyMedicinaRenal functionlcsh:Medicine030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyHypoglycemiaurologic and male genital diseases03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineChronic kidney diseaseMedicineMalalties cròniquesDiabetic kidney diseaseGlycemicKidneyProteinuriaKidney diseasesbusiness.industrylcsh:RType 2 Diabetes MellitusGeneral Medicinemedicine.diseasediabetic kidney diseasemedicine.anatomical_structureChronic diseasesMalalties del ronyómedicine.symptombusinessGLP-1chronic kidney diseaseKidney disease
researchProduct

The impact of occult renal failure on the cardiovascular risk stratification in an elderly population: the PREV-ICTUS study.

2008

To analyze the impact of occult renal failure (ORF) in the individual risk stratification and on the blood pressures (BP) and low-density lipoprotein (LDL) goals in an aged population, according to the ESH/ESC Hypertension Guidelines.A cross-sectional, population-based study on individuals aged 60 years or more carried out in Primary Care Centers of Spain. Kidney function was estimated from calculated creatinine clearance (eGFR), Cockroft and Gault formula. Ten-year cardiovascular risk was estimated through the ESH/ESC table including or not including the eGFR. Estimates of the modification in BP and LDL-cholesterol (cLDL) goals were calculated.In 6419 subjects, 4242 subjects (66%) had norm…

medicine.medical_specialtyMetabolic Clearance RatePopulationRenal functionBlood PressureIndividual riskNormal renal functionPopulation GroupsRisk FactorsInternal medicineElderly populationInternal MedicinemedicineHumansRenal InsufficiencyeducationAgededucation.field_of_studybusiness.industryGeneral MedicineCholesterol LDLMiddle AgedOccultEndocrinologyCross-Sectional StudiesLogistic ModelsCardiovascular DiseasesSpainCreatinineRisk stratificationHypertensionPractice Guidelines as TopicCardiology and Cardiovascular MedicinebusinessLipoproteinGlomerular Filtration RateBlood pressure
researchProduct

1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation

2019

Abstract Objectives The purpose of this study was to evaluate procedural and 1-year clinical and echocardiographic outcomes of patients treated with tricuspid edge-to-edge repair. Background Transcatheter edge-to-edge repair has been successfully performed in selected patients with symptomatic tricuspid regurgitation (TR) and high risk for surgery, but outcome data are sparse. Methods This analysis of the multicenter international TriValve (Transcatheter Tricuspid Valve Therapies) registry included 249 patients with severe TR treated with edge-to-edge repair in compassionate and/or off-label use. Clinical and echocardiographic outcomes were prospectively collected and retrospectively analyz…

medicine.medical_specialtyMitral regurgitationTricuspid valvebusiness.industryRenal functionRegurgitation (circulation)030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureInterquartile rangeInternal medicineConcomitantHeart failuremedicineCardiologySinus rhythm030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy.

2015

A previous animal study compared the nephrotoxic effect of ibandronate (IBN) and zoledronate (ZOL), but interpretation of these study results was limited because of the model of minimal nephrotoxic dosage with a dosage ratio of 1:3. The present study investigated the nephrotoxicity of ibandronate and zoledronate in a 1.5:1 dose ratio, as used in clinical practice and compared the nephrotoxicity in rats with normal and with mildly to moderately impaired renal function. We compared rats with normal renal function (SHAM) and with impaired renal function after unilateral nephrectomy (UNX), treated either with ibandronate 1.5mg/kg, zoledronate 1mg/kg or placebo once (1×) or nine (9×) times. Rena…

medicine.medical_specialtyNecrosisMedullary cavitymedicine.medical_treatmentRenal functionPlaceboKidneyNephrectomyZoledronic AcidNephrotoxicityInternal medicinemedicineAnimalsHumansRenal InsufficiencyRats WistarIbandronic AcidPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesUnilateral nephrectomyBisphosphonateRatsEndocrinologyToxicityFemalemedicine.symptombusinessPharmacological research
researchProduct

Temporary warm ischaemia, 5/6 nephrectomy and single uranylnitrate administration — comparison of three models intended to cause renal fibrosis in ra…

2001

In patients the progression of pathologic renal processes after the treatment of primary disease is a problem of increasing importance and therapeutic strategies are insufficient till now. The aim of this paper was to search for rat models of interstitial fibrosis as a basis for testing therapeutic strategies to prevent end-stage renal failure. Experiments were done on adult female Wistar rats (Han:Wist) to investigate long-term consequences of temporary warm ischaemia, 5/6 nephrectomy (5/6 NX) and single uranyl nitrate (UN) administration (0.3 or 0.5 mg/ 100 g body wt. intraperitoneally). Observation time was 20 weeks after injury in each group. Creatinine clearance, urinary protein excret…

medicine.medical_specialtyPathologyTime Factorsmedicine.medical_treatmentUrologyRenal functionKidneyToxicologyNephrectomyPathology and Forensic MedicineExcretionFibrosismedicineRenal fibrosisAnimalsRats WistarKidneybusiness.industryKidney metabolismCell BiologyGeneral Medicinemedicine.diseaseFibrosisNephrectomyRatsDisease Models AnimalHydroxyprolineProteinuriamedicine.anatomical_structureCreatinineReperfusion InjuryUranyl NitrateNephritis InterstitialFemalebusinessKidney diseaseExperimental and Toxicologic Pathology
researchProduct